Michael Weber, MD, PhD

Prospective Evaluation of Early Abciximab and Primary Percutaneous Intervention for Patients with ST Elevation Myocardial Infarc

08/01/2008

Stefan Horn , MD;

Karl-Ludwig Neuhaus , MD;

Uwe Zeymer , MD;

Ulrich Tebbe , MD;

Michael Weber , MD, PhD;

Rainer Jaksch , MD;

Karl-Otto Bischoff , MD;

Wolfgang Toepel , MD;

Parvaneh Marsalek , MD;

Cardiogenic shock occurs in about 10% of hospitalized patients with acute myocardial infarction (AMI).1 Despite the use of early reperfusion therapies with thrombolysis or percutaneous coronary intervention (PCI), the mortality in these...

Cardiogenic shock occurs in...

08/01/2008

Journal of Invasive Cardiology

Cardiac Safety of Esketamine Nasal Spray in Treatment-Resistant Depression: Results From the Clinical Development Program

Aim: To evaluate the cardiac safety of esketamine nasal spray administered to patients with treatment-resistant depression (TRD). Methods: Cardiovascular (CV) effects of esketamine nasal...

Jaskaran Singh , MD;

Teodora Doherty , MD;

Michael Weber , MD, PhD;

Ewa Wajs , MD, PhD;

Rama Melkote , MSc, MPH;

Janice Miller , MD;

11/22/2019